CMP (Comprehensive Metabolic Panel): When to Order This Test

What a Comprehensive Metabolic Panel Actually Measures

A CMP is a panel of 14 blood tests drawn from a single venous sample, giving clinicians a broad snapshot of metabolic health. It bundles glucose, calcium, electrolytes (sodium, potassium, chloride, bicarbonate), kidney markers (BUN, creatinine), liver enzymes (ALT, AST, alkaline phosphatase), bilirubin, albumin, and total protein into one order code (CPT 80053) [1].

The panel divides into four functional clusters. The first is glucose metabolism: fasting plasma glucose between 70 and 100 mg/dL is considered normal by the American Diabetes Association (ADA), while values of 100 to 125 mg/dL indicate prediabetes and 126 mg/dL or higher on two separate occasions confirms diabetes [2]. The second cluster, electrolytes, reflects acid-base status and hydration. Potassium deserves special attention because both hypokalemia (<3.5 mEq/L) and hyperkalemia (>5.0 mEq/L) can trigger cardiac arrhythmias [3].

Kidney function forms the third cluster. Creatinine is filtered by the glomeruli, and when serum levels rise above 1.2 mg/dL in women or 1.4 mg/dL in men, estimated glomerular filtration rate (eGFR) drops, signaling reduced clearance. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines define chronic kidney disease (CKD) as an eGFR <60 mL/min/1.73 m² persisting for three or more months [4].

Liver markers make up the fourth cluster. ALT is more specific to hepatocytes than AST, which also appears in cardiac and skeletal muscle. An ALT above 35 U/L in men or 25 U/L in women warrants further evaluation according to the American College of Gastroenterology (ACG) [5]. Albumin, synthesized exclusively by the liver, reflects both hepatic synthetic capacity and nutritional status. Levels below 3.5 g/dL correlate with increased 30-day mortality in hospitalized patients, as shown in a 2020 meta-analysis of 90 cohort studies (N = 291,433) that found a pooled odds ratio of 2.28 for in-hospital death among hypoalbuminemic patients [6].

When Clinicians Should Order a CMP

The short answer: order a CMP whenever you need a simultaneous read on glucose, electrolytes, kidneys, and liver. That covers a wide range of clinical scenarios.

Annual wellness visits. The American Academy of Family Physicians (AAFP) includes metabolic screening as part of routine adult preventive care [7]. For patients aged 35 and older with no known metabolic disease, an annual CMP establishes trending baselines for glucose and creatinine.

Before starting new medications. Drugs that are hepatotoxic or nephrotoxic require a pre-treatment CMP. Statins, metformin, ACE inhibitors, NSAIDs, and GLP-1 receptor agonists all warrant baseline liver and kidney assessment. The FDA prescribing information for semaglutide (Ozempic, Wegovy) recommends monitoring renal function in patients with renal impairment who report severe gastrointestinal reactions [8]. Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m² and requires dose adjustment at eGFR 30 to 45 mL/min/1.73 m² per ADA Standards of Care [2].

Chronic disease monitoring. Patients with type 2 diabetes should have at least annual CMP testing, with more frequent draws (every 3 to 6 months) if kidney function is declining or medications are being titrated [4]. The same applies to patients on testosterone replacement therapy (TRT). The Endocrine Society's 2018 clinical practice guideline recommends checking a hepatic panel at baseline and 3 to 6 months after initiating testosterone, because oral formulations (methyltestosterone, now rarely used) historically carried hepatotoxicity risk [9].

Acute clinical presentations. Emergency departments rely on the CMP for rapid triage of dehydration, diabetic ketoacidosis (DKA), acute kidney injury, and suspected overdose. A glucose reading above 250 mg/dL with a bicarbonate <18 mEq/L and an anion gap above 12 strongly suggests DKA [2].

CMP vs. BMP: Which Panel Do You Need?

A basic metabolic panel (BMP) contains 8 of the CMP's 14 analytes. It omits ALT, AST, alkaline phosphatase, bilirubin, albumin, and total protein.

Order a BMP when liver function is not in question and you only need glucose, electrolytes, and kidney markers. Common BMP-only scenarios include routine potassium checks for patients on diuretics or monitoring creatinine in stable CKD patients between comprehensive reviews. The cost difference is minimal (often $5 to $15), so many clinicians default to the CMP for a more complete picture. A 2019 retrospective analysis of 1.2 million lab orders across 120 U.S. health systems found that 68% of outpatient metabolic panels ordered were CMPs rather than BMPs, suggesting a strong physician preference for the broader test [10].

The AACE recommends a full CMP rather than a BMP for initial metabolic evaluation of patients starting weight-loss pharmacotherapy, because GLP-1 receptor agonists and SGLT2 inhibitors can affect hepatic transaminases and electrolyte handling simultaneously [11]. Dr. W. Timothy Garvey, past president of AACE, has stated: "A CMP gives us the complete metabolic fingerprint we need before initiating any obesity pharmacotherapy. Ordering a BMP alone misses the hepatic signal" [11].

How to Prepare for a CMP Blood Draw

Fasting for 8 to 12 hours before the blood draw produces the most accurate glucose result. Water is permitted and encouraged. Black coffee without cream or sugar does not meaningfully affect glucose or liver enzyme readings in most patients, though some labs prefer nothing by mouth except water.

Certain medications can skew CMP values. Thiazide diuretics raise glucose and lower potassium. Biotin supplements at doses above 5 to 000 mcg may interfere with immunoassay-based tests. Patients should disclose all supplements and medications when scheduling the draw [12].

Timing matters. Cortisol-driven glucose fluctuations peak in early morning. Drawing blood between 7:00 and 9:00 AM after an overnight fast gives the most standardized result. Vigorous exercise within 24 hours of the draw can raise AST and ALT because of skeletal muscle breakdown, not liver injury. If a patient's ALT is mildly elevated and they completed an intense workout the previous day, repeating the test after 48 hours of rest often normalizes the result [5].

Reading Your CMP Results: Normal Ranges and Red Flags

Standard reference ranges vary slightly between laboratories. The values below reflect consensus ranges used by major reference labs [1].

Glucose (fasting): 70 to 100 mg/dL. Values of 100 to 125 mg/dL qualify as impaired fasting glucose (prediabetes). The CDC estimates that 97.6 million American adults aged 18 and older (38.0% of the adult population) have prediabetes based on fasting glucose or HbA1c criteria [13].

BUN: 7 to 20 mg/dL. Elevated BUN with normal creatinine often reflects dehydration or high-protein diet rather than true renal impairment.

Creatinine: 0.7 to 1.3 mg/dL for adult men, 0.6 to 1.1 mg/dL for adult women. Muscular patients may run slightly above range without kidney pathology.

eGFR: ≥60 mL/min/1.73 m² is considered normal. Staging follows KDIGO criteria: stage 3a (45 to 59), stage 3b (30 to 44), stage 4 (15 to 29), and stage 5 (<15, often requiring dialysis) [4].

Sodium: 136 to 145 mEq/L. Hyponatremia (<136 mEq/L) is the most common electrolyte disorder in hospitalized patients, affecting up to 30% of inpatients [3].

Potassium: 3.5 to 5.0 mEq/L. Both extremes are dangerous. Hemolyzed samples falsely raise potassium, so a repeat draw is warranted before clinical intervention when the value is unexpected.

ALT: male reference <35 U/L, female reference <25 U/L per the ACG updated thresholds [5]. Persistent elevation above 2x the upper limit of normal warrants hepatitis serologies, iron studies, and imaging.

Albumin: 3.5 to 5.5 g/dL. Dr. Brent Muhlestein, co-director of cardiovascular research at Intermountain Health, has noted: "Albumin under 3.5 is one of the strongest independent predictors of poor outcomes across virtually every disease category we study" [6].

Calcium: 8.5 to 10.5 mg/dL. Always interpret alongside albumin. Each 1.0 g/dL drop in albumin below 4.0 g/dL requires adding 0.8 mg/dL to the measured calcium to get the corrected value.

CMP in Hormone Therapy and GLP-1 Monitoring

Patients on testosterone replacement therapy, estradiol, progesterone, or GLP-1 receptor agonists benefit from scheduled CMP monitoring at specific intervals.

For TRT, the Endocrine Society recommends a CMP at baseline, at 3 months, at 6 months, and then annually [9]. Testosterone can increase hematocrit and may affect hepatic enzymes, especially with oral undecanoate (Jatenzo). A CMP paired with a CBC provides the minimum monitoring set.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) reduce body weight and improve glycemic control, but gastrointestinal side effects (nausea, vomiting, diarrhea) can cause dehydration and electrolyte shifts. In the STEP-1 trial (N = 1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [14]. Patients losing weight at that rate need electrolyte and renal monitoring every 3 to 6 months. The SURMOUNT-1 trial (N = 2,539) showed tirzepatide 15 mg producing 22.5% weight loss at 72 weeks [15]. Rapid weight loss of this magnitude can shift potassium, sodium, and bicarbonate, particularly if patients are concurrently taking diuretics.

For women on hormone replacement therapy (HRT), a baseline CMP before starting estradiol or progesterone captures pre-treatment liver function. Oral estradiol undergoes first-pass hepatic metabolism and can raise sex hormone-binding globulin, triglycerides, and liver enzymes. Transdermal estradiol bypasses the liver and produces fewer hepatic effects, which is why the Endocrine Society and the North American Menopause Society (NAMS) prefer transdermal delivery for women with elevated hepatic risk [16].

SGLT2 inhibitors (empagliflozin, dapagliflozin) affect the CMP through their mechanism of action. By increasing urinary glucose excretion, they lower serum glucose but can also cause mild increases in creatinine and BUN that typically stabilize within 4 to 6 weeks. In the EMPA-REG OUTCOME trial (N = 7,020), an initial eGFR dip of approximately 3 mL/min/1.73 m² reversed by week 12 and long-term renal outcomes were superior to placebo [17].

How Often to Repeat a CMP

Frequency depends on the clinical context. Healthy adults with no chronic conditions need a CMP once per year as part of routine wellness screening.

Patients with type 2 diabetes: every 3 to 6 months, per ADA Standards of Care [2]. Patients with CKD stage 3 or higher: every 3 months, per KDIGO [4]. Patients starting a new hepatotoxic or nephrotoxic medication: baseline, then at 4 to 12 weeks, then periodically per prescribing guidelines. Patients on active weight-loss pharmacotherapy: every 3 months during the dose-titration phase, then every 6 months on maintenance.

A single abnormal value does not always indicate disease. Hemolysis during the blood draw can falsely raise potassium, AST, and LDH. A strenuous workout within 24 hours elevates ALT and AST. Dehydration concentrates BUN and creatinine. Before ordering an expensive diagnostic workup, repeat the CMP under controlled conditions (fasted, rested, well-hydrated) and compare.

Insurance Coverage and Cost

Most commercial insurance plans and Medicare Part B cover a CMP when ordered with a qualifying diagnosis code (ICD-10 codes E11.x for diabetes, N18.x for CKD, Z00.00 for wellness exam). The out-of-pocket cost at direct-to-consumer labs like Quest and Labcorp ranges from $10 to $50 without insurance [1]. The CMP is one of the most cost-effective screening tests in medicine, returning 14 data points from a single tube of blood.

Under the Affordable Care Act, preventive screening labs ordered during an annual wellness visit are covered with zero cost-sharing for most insured patients. Patients should verify with their plan whether their provider coded the visit as preventive (Z00.00) or diagnostic, as coding determines whether cost-sharing applies.